Skip to main content

Blog Exposure - FDA Approves Eli Lilly's Taltz(R) for the Treatment of Active PsA

Stock Monitor: AstraZeneca Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 05, 2017 / Active-Investors issued a free report on Eli Lilly and Co. (NYSE: LLY), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=LLY as the Company's latest news hit the wire. On December 01, 2017, the Company declared that the US Food and Drug Administration (FDA) has granted approval to Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA). Sign up now for our free research reports at:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for AstraZeneca PLC (NYSE: AZN), which also belongs to the Healthcare sector as the Company Eli Lilly. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=AZN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Eli Lilly most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:

www.active-investors.com/registration-sg/?symbol=LLY

On November 08, 2017, the Company announced that patients with active PsA treated with Taltz®, who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks.

SPIRIT-P1 and SPIRIT-P2 Clinical Trials

The efficacy and safety of Taltz® was determined from findings from two randomized, double-blind, placebo-controlled Phase-3 studies, SPIRIT-P1 and SPIRIT-P2, that included more than 670 adult patients with active PsA. SPIRIT-P1 evaluated the safety and efficacy of Taltz® compared to placebo in patients with active PsA who had never been treated with a biologic disease-modifying anti-rheumatic drug. SPIRIT-P2 evaluated the safety and efficacy of Taltz® compared to placebo in tumor necrosis factor inhibitor (TNFi)-experienced patients with active PsA who failed one or two TNFis. The results from both studies demonstrated that patients treated with Taltz® achieved significant improvement in joint symptoms compared to placebo.

Taltz® Received FDA Approval for Treatment of Moderate-to-Severe Plaque Psoriasis in 2016

On March 22, 2016, the FDA first approved Taltz® for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Other Companies Receiving FDA Approval for Treating PsA in 2017

  • In July 2017, the FDA approved Bristol-Myers Squibb Co.'s ORENCIA for the treatment of adults with active PsA. ORENCIA is approved and available in both intravenous and subcutaneous injection formulations.
  • In August 2017, the FDA's Arthritis Advisory Committee voted to recommend approval of the proposed dose of Pfizer's tofacitinib for the treatment of adult patients with active PsA. Pfizer submitted supplemental new drug applications for XELJANZ® and XELJANZ® XR for this pending indication. The FDA's decision is expected by December 2017.
  • In October 2017, the FDA approved Janssen Biotech's SIMPONI ARIA® (golimumab) for the treatment of adults with active PsA or active ankylosing spondylitis.

About Psoriatic Arthritis (PsA)

PsA is a form of arthritis that in most cases affects the skin and the joints, causing swelling, stiffness, and pain in and around the joints and impaired physical function. It occurs when an overactive immune system sends out faulty signals that cause inflammation, leading to swollen and painful joints and tendons. Psoriatic arthritis symptoms and signs include low back pain, scaly rashes, conjunctivitis, reduced range of motion, swollen joints, among others.

About Taltz® (ixekizumab)

Taltz® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, or pills, or phototherapy. Taltz® may be administered alone or in combination with a conventional disease-modifying anti-rheumatic drug. It should not be used in patients with a previous serious hypersensitivity reaction. Other warnings and precautions for Taltz® include pre-treatment evaluation for tuberculosis, hypersensitivity reactions, inflammatory bowel disease, and immunizations. The most common adverse reactions associated with Taltz® treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

About Eli Lilly and Co.

Founded in 1876, Eli Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. The Company's employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of diseases, and give back to communities through philanthropy and volunteerism. The Company is headquartered in Indianapolis, Indiana.

Stock Performance Snapshot

December 04, 2017 - At Monday's closing bell, Eli Lilly's stock marginally climbed 0.30%, ending the trading session at $85.58.

Volume traded for the day: 4.23 million shares, which was above the 3-month average volume of 3.24 million shares.

Stock performance in the last month – up 2.95%; previous three-month period – up 7.22%; past twelve-month period – up 26.39%; and year-to-date - up 16.36%

After yesterday's close, Eli Lilly's market cap was at $94.59 billion.

Price to Earnings (P/E) ratio was at 40.75.

The stock has a dividend yield of 2.43%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.